0001209191-21-046554.txt : 20210713 0001209191-21-046554.hdr.sgml : 20210713 20210713170031 ACCESSION NUMBER: 0001209191-21-046554 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210712 FILED AS OF DATE: 20210713 DATE AS OF CHANGE: 20210713 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fust Matthew K CENTRAL INDEX KEY: 0001397266 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 211088506 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-12 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001397266 Fust Matthew K C/O CRINETICS PHARMACEUTICALS, INC. 10222 BARNES CANYON ROAD, BLDG 2 SAN DIEGO CA 92121 1 0 0 0 Common Stock 2021-07-12 4 M 0 5000 1.91 A 17536 D Common Stock 2021-07-12 4 S 0 5000 20.71 D 12536 D Non-qualified stock option (Right to Buy) 1.91 2021-07-12 4 M 0 5000 0.00 D 2028-03-16 Common stock 5000 37092 D The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.71. The range of sales prices on the transaction date was $20.54 to $21.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. /s/ Marc Wilson, as attorney-in-fact 2021-07-13